Traveler's diarrhea a clinical review

JAMA - Journal of the American Medical Association

Volumn 313, Issue 1, 2015, Pages 71-80

  Steffen, Robert ^a,b   Hill, David R ^c   DuPont, Herbert L ^b,d,e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c New York   (United States)

^d CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BISMUTH SALICYLATE; CIPROFLOXACIN; LOPERAMIDE; RIFAXIMIN; ANTIINFECTIVE AGENT;

ACHILLES TENDINITIS; CHEMOPROPHYLAXIS; CHRONIC DIARRHEA; CLINICAL EVALUATION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEVER; HELP SEEKING BEHAVIOR; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; IRRITABLE COLON; NAUSEA; PERSONAL HYGIENE; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; RISK REDUCTION; SELF CARE; STOMACH PROTECTION; TRAVELLER DIARRHEA; COMPLICATION; DIARRHEA; HYGIENE; IRRITABLE BOWEL SYNDROME; TRAVEL;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CIPROFLOXACIN; DIARRHEA; HUMANS; HYGIENE; IRRITABLE BOWEL SYNDROME; RISK FACTORS; TRAVEL;

EID: 84920542520     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.17006     Document Type: Review

References (124)

1. Kean BH. The diarrhea of travelers toMexico: Summary of 5-year study. Ann Intern Med. 1963;59: 605-614
2. Gorbach SL, Kean BH, Evans DG, Evans DJ Jr, Bessudo D. Travelers' diarrhea and toxigenic Escherichia coli.NEngl J Med. 1975;292(18):933-936
3. DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med. 1982;307 (14):841-844
4. Freedman DO,Weld LH, Kozarsky PE, et al; GeoSentinel Surveillance Network. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;354(2):119-130
5. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis. 2005;41(suppl 8):S531-S535
6. DuPont HL, Ericsson CD, FarthingMJ, et al. Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med. 2009;16(3): 161-171
7. DuPont HL, Ericsson CD, FarthingMJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16(3):149-160
8. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: Systematic review from 1973 to the present. Am J Trop Med Hyg. 2009;80(4): 609-614
9. Hill DR, Beeching NJ. Travelers' diarrhea. Curr Opin Infect Dis. 2010;23(5):481-487
10. Angst F, Steffen R. Update on the epidemiology of traveler's diarrhea in East Africa. J Travel Med. 1997;4(3):118-120
11. Health Protection Agency. Foreign Travel-Associated Illness-a Focus on Travellers' Diarrhoea. London, England: Health Protection Agency; 2010
12. Hagmann S, Neugebauer R, Schwartz E, et al; GeoSentinel Surveillance Network. Illness in children after international travel: Analysis from the GeoSentinel Surveillance Network. Pediatrics. 2010;125(5):e1072-e1080
13. PiyaphaneeW, Kusolsuk T, Kittitrakul C, SuttithumW, Ponam T, Wilairatana P. Incidence and impact of travelers' diarrhea among foreign backpackers in Southeast Asia: A result from Khao San Road, Bangkok. J Travel Med. 2011;18(2):109-114
14. Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis. 2005;41(suppl 8):S536-S540
15. Greenwood Z, Black J,Weld L, et al; GeoSentinel Surveillance Network. Gastrointestinal infection among international travelers globally. J Travel Med. 2008;15(4):221-228
16. Pitzurra R, Steffen R, Tschopp A, Mütsch M. Diarrhoea in a large prospective cohort of European travellers to resource-limited destinations. BMC Infect Dis. 2010;10:231
17. Steffen R, Tornieporth N, Clemens SA, et al. Epidemiology of travelers' diarrhea: Details of a global survey. J Travel Med. 2004;11(4):231-237
18. Belderok SM, van den Hoek A, Kint JA, Schim van der LoeffMF, Sonder GJ. Incidence, risk factors and treatment of diarrhoea among Dutch travellers: Reasons not to routinely prescribe antibiotics. BMC Infect Dis. 2011;11:295
19. Soonawala D, Vlot JA, Visser LG. Inconvenience due to travelers' diarrhea: A prospective follow-up study. BMC Infect Dis. 2011;11:322
20. Chongsuvivatwong V, Chariyalertsak S, McNeil E, et al. Epidemiology of travelers' diarrhea in Thailand. J Travel Med. 2009;16(3):179-185
21. Mues KE, Esposito DH, Han PV, Jentes ES, Sotir MJ, Brown C. Analyzing GeoSentinel surveillance data: A comparison of methods to explore acute gastrointestinal illness among international travelers. Clin Infect Dis. 2014;58(4):546-554
22. Steffen R, van der Linde F, Gyr K, Schär M. Epidemiology of diarrhea in travelers. JAMA. 1983; 249(9):1176-1180
23. Bavishi C, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11-12):1269-1281
24. Jiang ZD, DuPont HL, Garey K, et al. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006;101(5):1112-1116
25. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: Polymorphism in the interleukin-8 promoter region. J Infect Dis. 2003;188(4):506-511
26. Mohamed JA, DuPont HL, Jiang ZD, et al. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers toMexico. Clin Infect Dis. 2007;44(7):945-952
27. Flores J, DuPont HL, Lee SA, et al. Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol. 2008;15(8):1194-1198
28. Mohamed JA, DuPont HL, Jiang ZD, et al. A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers toMexico. J Infect Dis. 2009;199(4):477-485
29. Mohamed JA, DuPont HL, Flores J, et al. Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers toMexico. Clin Infect Dis. 2011;52(11):1332-1341
30. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun. 2005;73(11):7422-7427
31. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9(5):548-553
32. Fletcher SM, Maharaj SR, James K. Description of the food safety system in hotels and how it compares with HACCP standards. J Travel Med. 2009;16(1):35-41
33. Cartwright RY. Food and waterborne infections associated with package holidays. J Appl Microbiol. 2003;94(suppl):12S-24S
34. Ashley DV,Walters C, Dockery-Brown C, McNab A, Ashley DE. Interventions to prevent and control food-borne diseases associated with a reduction in traveler's diarrhea in tourists to Jamaica. J Travel Med. 2004;11(6):364-367
35. Huang DB, Sanchez AP, Triana E, Jiang ZD, DuPont HL, Ericsson CD. United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. J Travel Med. 2004;11(3):143-145
36. Launders NJ, Nichols GL, Cartwright R, Lawrence J, Jones J, Hadjichristodoulou C. Self-reported stomach upset in travellers on cruise-based and land-based package holidays. PLoS One. 2014;9(1):e83425
37. Wikswo ME, Cortes J, Hall AJ, et al. Disease transmission and passenger behaviors during a high morbidity norovirus outbreak on a cruise ship, January 2009. Clin Infect Dis. 2011;52(9):1116-1122
38. Paredes-ParedesM, Okhuysen PC, Flores J, et al. Seasonality of diarrheagenic Escherichia coli pathotypes in the US students acquiring diarrhea in Mexico. J Travel Med. 2011;18(2):121-125
39. Soller JA, Bartrand T, Ashbolt NJ, Ravenscroft J, Wade TJ. Estimating the primary etiologic agents in recreational freshwaters impacted by human sources of faecal contamination. Water Res. 2010; 44(16):4736-4747
40. Hlavsa MC, Roberts VA, Kahler AM, et al; Centers for Disease Control and Prevention. Recreational water-associated disease outbreaks-United States, 2009-2010. MMWR Morb Mortal Wkly Rep. 2014;63(1):6-10
41. Herbinger KH, Drerup L, Alberer M, Nothdurft HD, Sonnenburg FV, Löscher T. Spectrum of imported infectious diseases among children and adolescents returning from the tropics and subtropics. J Travel Med. 2012;19(3):150-157
42. Hunziker T, Berger C, Staubli G, et al. Profile of travel-associated illness in children, Zürich, Switzerland. J Travel Med. 2012;19(3):158-162
43. Gautret P, Gaudart J, Leder K, et al; GeoSentinel Surveillance Network. Travel-associated illness in older adults (>60 y). J Travel Med. 2012;19(3):169-177
44. Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg. 2000;62 (5):585-589
45. Schlagenhauf P, Chen LH, Wilson ME, et al; GeoSentinel Surveillance Network. Sex and gender differences in travel-associated disease. Clin Infect Dis. 2010;50(6):826-832
46. Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP. Health risks of travelers with medical conditions-a retrospective analysis. J Travel Med. 2012;19(2):104-110
47. Baaten GG, Geskus RB, Kint JA, Roukens AH, Sonder GJ, van den Hoek A. Symptoms of infectious diseases in immunocompromised travelers: A prospective study with matched controls. J Travel Med. 2011;18(5):318-326
48. Sebeny PJ, Nakhla I, Moustafa M, et al. Hotel clinic-based diarrheal and respiratory disease surveillance in US service members participating in Operation Bright Star in Egypt, 2009. Am J Trop Med Hyg. 2012;87(2):312-318
49. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers toMexico. Am J Gastroenterol. 2004;99(9):1774-1778
50. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? a prospective study. Clin Infect Dis. 2006;43(7):898-901
51. Mütsch M, Pitzurra R, Hatz C, Steffen R. Post-infectious sequelae of travelers' diarrhea: Irritable bowel syndrome. J Travel Med. 2014;21(2): 141-143
52. Connor BA, RiddleMS. Post-infectious sequelae of travelers' diarrhea. J Travel Med. 2013;20(5): 303-312
53. Pitzurra R, FriedM, Rogler G, et al. Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations. J Travel Med. 2011;18(4):250-256
54. Nair P, Okhuysen PC, Jiang ZD, et al. Persistent abdominal symptoms in US adults after short-term stay in Mexico. J Travel Med. 2014;21(3):153-158
55. DuPont HL, Galler G, Garcia-Torres F, Dupont AW, Greisinger A, Jiang ZD. Travel and travelers' diarrhea in patients with irritable bowel syndrome. Am J Trop Med Hyg. 2010;82(2):301-305
56. Jackson BR, Zegarra JA, Lopez-Gatell H, et al; GBS Outbreak Investigation Team. Binational outbreak of Guillain-Barré syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol Infect. 2014;142(5):1089-1099
57. Jiang ZD, Dupont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: Importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol. 2010;48(4):1417-1419
58. Galbadage T, Jiang ZD, DuPont HL. Improvement in detection of enterotoxigenic Escherichia coli in patients with travelers' diarrhea by increasing the number of E coli colonies tested. Am J Trop Med Hyg. 2009;80(1):20-23
59. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg. 2006;74(6):1060-1066
60. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis. 2002;185(4):497-502
61. Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol. 2010;48(5): 1673-1676
62. Pandey P, Bodhidatta L, LewisM, et al. Travelers' diarrhea in Nepal: An update on the pathogens and antibiotic resistance. J Travel Med. 2011;18(2):102-108
63. Swaminathan A, Torresi J, Schlagenhauf P, et al; GeoSentinel Network. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect. 2009;59(1):19-27
64. RiddleMS, Sanders JW, Putnam SD, Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): A systematic review. Am J Trop Med Hyg. 2006;74(5):891-900
65. Kayman T, Abay S, Hizlisoy H, Atabay HI, Diker KS, Aydin F. Emerging pathogen Arcobacter spp in acute gastroenteritis: Molecular identification, antibiotic susceptibilities and genotyping of the isolated arcobacters. J Med Microbiol. 2012; 61(pt 10):1439-1444
66. Mandisodza O, Burrows E, Nulsen M. Arcobacter species in diarrhoeal faeces from humans in New Zealand. N Z Med J. 2012;125(1353): 40-46
67. Lääveri T, Pakkanen SH, Antikainen J, et al. High number of diarrhoeal co-infections in travellers to Benin,West Africa. BMC Infect Dis. 2014;14:81
68. Frank C,Werber D, Cramer JP, et al; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365(19): 1771-1780
69. Hadler JL, Clogher P, Hurd S, et al. Ten-year trends and risk factors for non-O157 Shiga toxin-producing Escherichia coli found through Shiga toxin testing, Connecticut, 2000-2009. Clin Infect Dis. 2011;53(3):269-276
70. KendallME, Crim S, Fullerton K, et al. Travel-associated enteric infections diagnosed after return to the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009. Clin Infect Dis. 2012;54(suppl 5): S480-S487
71. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: Randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44(3): 338-346
72. Antikainen J, Kantele A, Pakkanen SH, et al. A quantitative polymerase chain reaction assay for rapid detection of 9 pathogens directly from stools of travelerswith diarrhea. Clin Gastroenterol Hepatol. 2013;11(10):1300-1307.e3
73. Youmans BP, Ajami NJ, Jiang ZD, Petrosino JF, DuPont HL, Highlander SK. Development and accuracy of quantitative real-time polymerase chain reaction assays for detection and quantification of enterotoxigenic Escherichia coli (ETEC) heat labile and heat stable toxin genes in travelers' diarrhea samples. Am J Trop Med Hyg. 2014;90(1):124-132
74. Meraz IM, Jiang ZD, Ericsson CD, et al. Enterotoxigenic Escherichia coli and diffusely adherent E coli as likely causes of a proportion of pathogen-negative travelers' diarrhea-a PCR-based study. J Travel Med. 2008;15(6):412-418
75. DuPont HL, Haake R, Taylor DN, et al. Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med. 2007;14(1):16-19
76. Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. Enteropathogens and chronic illness in returning travelers. N Engl J Med. 2013;368(19): 1817-1825
77. Kozicki M, Steffen R, Schär M. "Boil it, cook it, peel it or forget it": Does this rule prevent travellers' diarrhoea? Int J Epidemiol. 1985;14(1):169-172
78. Bandres JC, Mathewson JJ, DuPont HL. Heat susceptibility of bacterial enteropathogens: Implications for the prevention of travelers' diarrhea. Arch Intern Med. 1988;148(10):2261-2263
79. Koo HL, Jiang ZD, Brown E, Garcia C, Qi H, Dupont HL. Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. Clin Infect Dis. 2008; 47(2):218-221
80. Teague NS, Srijan A,Wongstitwilairoong B, et al. Enteric pathogen sampling of tourist restaurants in Bangkok, Thailand. J Travel Med. 2010;17(2):118-123
81. Dickens DL, DuPont HL, Johnson PC. Survival of bacterial enteropathogens in the ice of popular drinks. JAMA. 1985;253(21):3141-3143
82. DuPont HL, Ericsson CD, Johnson PC, Bitsura JAM, DuPontMW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA. 1987;257(10):1347-1350
83. Rademaker CM, Hoepelman IM,Wolfhagen MJ, Beumer H, Rozenberg-ArskaM, Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis. 1989;8(8):690-694
84. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142(10):805-812
85. DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending aMexican university. Gastroenterology. 1977;73(4 pt 1):715-718
86. Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA,Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA. 1986;255(6):757-760
87. Salam I, Katelaris P, Leigh-Smith S, Farthing MJG. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet. 1994;344(8936): 1537-1539
88. Gross PA, Barrett TL, Dellinger EP, et al; Infectious Diseases Society of America. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18(3):421
89. McFarland LV.Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007;5(2):97-105
90. Virk A, Mandrekar J, Berbari EF, et al. A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers' diarrhea. J Travel Med. 2013;20(2):88-94
91. Rao G, Aliwalas MG, Slaymaker E, Brown B. Bismuth revisited: An effective way to prevent travelers' diarrhea. J TravelMed. 2004;11(4):239-241
92. Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy withmyoclonus. Mov Disord. 1995;10(2):220-222
93. Hu Y, Ren J, Zhan M, LiW, Dai H. Efficacy of rifaximin in prevention of travelers' diarrhea: Ameta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19(6): 352-356
94. Zanger P, Nurjadi D, Gabor J, Gaile M, Kremsner PG. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2013;13(11):946-954
95. Ruiz J, Pons MJ. Prevention of travellers' diarrhoea: where and who? Lancet Infect Dis. 2013; 13(11):911-912
96. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42(9):1283-1288
97. DuPont HL. Systematic review: The epidemiology and clinical features of travellers' diarrhoea. Aliment Pharmacol Ther. 2009;30(3): 187-196
98. Alajbegovic S, Sanders JW, Atherly DE, Riddle MS. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): A systematic review and meta-analysis. Syst Rev. 2012;1:39
99. Hill DR, Ericsson CD, Pearson RD, et al; Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43(12):1499-1539
100. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2014;1:CD001261
101. Greenaway CA, Schofield S, Henteleff A, et al. Statement on international travellers and typhoid by the Committee to Advise on Tropical Medicine and Travel (CATMAT). Can Commun Dis Rep. 2014; 40(4):60-70
102. Lundkvist J, Steffen R, Jönsson B. Cost-benefit ofWC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea. J Travel Med. 2009;16(1):28-34
103. Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006;6(6):361-373
104. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis. 2005;5(6):349-360
105. Caeiro JP, DuPont HL, Albrecht H, Ericsson CD. Oral rehydration therapy plus loperamide vs loperamide alone in the treatment of traveler's diarrhea. Clin Infect Dis. 1999;28(6):1286-1289
106. Freedman SB, Ali S, Oleszczuk M, Gouin S, Hartling L. Treatment of acute gastroenteritis in children: An overview of systematic reviews of interventions commonly used in developed countries. Evid Based Child Health. 2013;8(4):1123-1137
107. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048
108. Salari P, Nikfar S, Abdollahi M. Ameta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets. 2012;11(1):3-14
109. RitchieML, Romanuk TN. Ameta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938
110. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers' diarrhoea. Cochrane Database Syst Rev. 2000;(3):CD002242
111. Ouyang-Latimer J, Jafri S, VanTassel A, et al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers toMexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother. 2011;55(2):874-878
112. Bottieau E, Clerinx J, Vlieghe E, et al. Epidemiology and outcome of Shigella, Salmonella and Campylobacter infections in travellers returning from the tropics with fever and diarrhoea. Acta Clin Belg. 2011;66(3):191-195
113. Pollett S, Rocha C, Zerpa R, et al. Campylobacter antimicrobial resistance in Peru: A 10-year observational study. BMC Infect Dis. 2012; 12:193
114. RayWA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-1890
115. Hopkins KL, Mushtaq S, Richardson JF, et al. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK. Int J Antimicrob Agents. 2014;43(5):431-437
116. DuPont HL, Petersen A, Zhao J, et al. Targeting of rifamycin SV to the colon for treatment of treatment of travelers' diarrhea: A randomized, double-blind, placebo-controlled phase 3 study. J Travel Med. 2014;21(6):369-376
117. RiddleMS, Connor BA, Tribble DR. Targeted therapy in travelers' diarrhea: what is the role for the non-absorbable? J Travel Med. 2014;21(6):365-368
118. RiddleMS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: A systematic review and meta-analysis. Clin Infect Dis. 2008;47(8):1007-1014
119. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin vs ciprofloxacin for the treatment of traveler's diarrhea: A randomized, double-blind clinical trial. Clin Infect Dis. 2001;33(11):1807-1815
120. DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med. 2014;370 (16):1532-1540
121. McGregor AC, Whitty CJ,Wright SG. Geographic, symptomatic and laboratory predictors of parasitic and bacterial causes of diarrhoea in travellers. Trans R Soc Trop Med Hyg. 2012;106(9): 549-553
122. Neuberger A, Saadi T, Shetern A, Schwartz E. Clostridium difficile infection in travelers-a neglected pathogen? J Travel Med. 2013;20(1):37-43
123. Soonawala D, van Lieshout L, den Boer MA, et al. Post-travel screening of asymptomatic long-term travelers to the tropics for intestinal parasites using molecular diagnostics. Am J Trop Med Hyg. 2014;90(5):835-839
124. Svennerholm AM, Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines. 2012;11(4):495-507.